Home
Issues
Aim & Scope
Open Access
Indexing
Why publish with us
Contact
Editorial Board
Instructions to Authors (PDF)
Manuscript Types
Manuscript Formatting
How to submit
Preprints
Authorship & COI
Principles of Transparency Checklist
Publication Ethics and Publication Malpractice Statement
CrossMark
Data Policies
SHORT REVIEW
Chronic Obstructive Pulmonary Disease
Corresponding author
J. Politis
Northeastern Ohio Universities College of Medicine, 500 Gypsy Lane, PO Box 240, Youngstown, Ohio 44501-0240
Northeastern Ohio Universities College of Medicine, 500 Gypsy Lane, PO Box 240, Youngstown, Ohio 44501-0240
Pneumon 2000;13(1):36-49
KEYWORDS
chronic obstructive pulmonary diseasebronchodilatorsdiagnosisexacerbationsmokingantibioticscorticosteroidsoxygen therapymechanical ventilation
REFERENCES (90)
1.
American Thoracic Society Standards for the diagnosis and care of patients with Chronic Obstructive Pulmonary Disease. Am Rev Respir Crit Care Med 1995, 152: 577-620.
3.
Ventura SJ et al. Births and Deaths: United States 1996 Monthly Vital Statistics Report Vol 46, No 1, Suppl 2. National Center for Health Statistics, 1997.
4.
Feinleib M et al. Trends in COPD mortality in the United States. Am Rev Respir Dis 1989, 140: 59-518.
6.
American Thoracic Society. Standardization of spirometry: 1994 update. Am J Respir Crit Care Med 1995, 152: 1107-1136.
8.
Hankinson JL. Office Spirometry. Does your quality render it impractical? Chest 1999, 116: 276-277.
9.
Strategies in preserving lung health and preventing COPD and associated diseases: The National Lung Health Education Program (NHLEP) Chest 1998, 113 (suppl): 1235-1555.
10.
Ferguson GT et al. Office spirometry for lung health in adults: a report of the ACCP/NHLBI consensus conference for the National Lung Health Education Program (draft) March 1999.
11.
Gross NJ: Practical lessons from the Lung Health Study. J Respir Dis 1995, 16: 162-169.
12.
Semmungal TAR et al. Effect of Exacerbation on Quality of Life in Patients with COPD . Am J Respir Crit Care Med 1998, 157: 1418-1422.
13.
Connors AF et al. Outcomes following acute exacerbations of severe chronic obstructive lung disease. Am J Respir Crit Care Med 1996, 154: 959-967.
14.
Nichol KL et al. Relation Between Influenza Vaccination and Outpatient Visits, Hospitalization and Mortality in Elderly Persons with Chronic Lung Disease. Ann Intern Med 1999, 130: 397-403.
15.
Nichol KL et al. Effectiveness of Live, Attenuated Intranasal Influenza Virus Vaccine in Healthy, Working Adults. A randomized controlled trial. JAMA 1999, 282: 137-144.
16.
Monto AS et al. Zanamivir in the Prevention of Influenza Among Healthy Adults. JAMA 1999, 282: 31-35.
17.
Fletcher C, Peto R: The natural history of chronic airflow obstruction Br Med J 1977, 1645-1648.
18.
Bergen AW, Caporaso N: Cigarette Smoking. J Natl Cancer Inst 1999, 91: 1365-1375.
19.
Hughes JR et al. Recent Advances in the Pharmacotherapy of Smoking 1999, 281: 72-76.
20.
Tonnesen P et al. Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. Eur. Respir. J 1999, 13: 238-246.
21.
Hurt RD et al. A comparison of sustained-release bupropion and placebo for smoking cessation. NEJM 1997, 337: 1195-1202.
22.
Jorenby DE et al. A controlled trial of sustained release Bupropion, a nicotine patch, or both for smoking cessation. N. Engl. J. Med 1999, 340: 685-691.
23.
Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Ann J Respir Crit Care Med 1997, 155: 1283-1289.
24.
Celli B, Snider Gil et al. ATS Statement: Standards for the diagnosis and care of patients with COPD. Am J Respir Crit Care Med. 1995, 152: 577-120.
25.
Mahler DA et al. Efficacy of Salmeterol Xinafoate in the treatment of COPD. Chest 1999, 115: 957-965.
27.
Martin RJ et al. Effect of Ipratropium Bromide Treatment on Oxygen Saturation and Sleep Quality in COPD. Chest 1999, 115: 1338-1345.
28.
Dorinsky PM et al. The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD. Chest 1999, 115: 966- 971.
29.
Friedman M et al. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest 1999, 115: 636-641.
30.
Guyatt GH et al. Bronchodilators in chronic airflow limitation. Am Rev Respir Dis. 1987, 137: 1069-1074.
31.
Tsukino M et al. Effects of theophylline and ipratropium bromide on exercise performance in patients with stable COPD. Thorax 1998, 53: 269-273.
32.
Karpel JP et al. A comparison of inhaled ipratropium, oral theophylline plus inhaled beta agonist, and the combination of all three in patients with COPD. Chest 1994, 105: 1089-1094.
33.
Brenner P et al. Cardiovascular effects of fenoterol under conditions of hypoxemia. Thorax 1992, 47: 814- 817.
34.
Cazzola M et al. Cardiac effects of Formoterol and Salmeterol in Patients Suffering from COPD with Preexisting Cardiac Arrhythmias and Hypoxemia. Chest 1998, 114: 411-415.
35.
Tranfa CME et al. Short-term Cardiovascular Effects of Salmeterol. Chest 1998, 113:1272-1276.
36.
Jenne JW. The debate on S-enantiomers of b-agonists: Tempest in a teapot or gathering storm? N Allergy Clin Immunol 1998, 102: 893-895.
37.
Monso E et al. Bacterial infection in COPD. A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med. 1995, 152: 1316-1320.
38.
Eller J et al. Infective exacerbations: Relation between bacteriologic etiology and lung function. Chest 1998, 113: 1542-1548.
39.
Soler N et al. Bronchial microbial patterns in severe exacerbations of COPD requiring Mechanical Ventilation. Am J Respir Crit Care Med 1998, 157: 1498-1505.
40.
Miravitlles et al. Relationship between bacterial flora in sputum and Functional Impairment in Patients with Acute Exacerbations of COPD. Chest 1999, 116:40-46.
41.
Anthonisen NR et al. Antibiotic therapy in acute exacerbations of COPD. Ann Intern Med 1987, 106: 196- 204.
42.
Saint S et al. Antibiotics in COPD exacerbations: A meta analysis. JAMA 1995, 273: 957-960.
43.
Balter MS et al. Recommendations on the management of chronic bronchitis. Can Med Assoc J 1994, 151(10 suppl): 5-23.
44.
Callahan CM et al. Oral corticosteroid therapy for patients with stable COPD: a meta analysis. Ann Intern Med 1991, 114: 216-223.
45.
Chanez P et al. Corticosteroid reversibility in COPD is related to features of asthma. Am J Respir Crit Care Med 1997, 15 5: 1529-34.
46.
Pizzichini E et al. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med 1998, 158: 1511- 1517.
47.
Niewoehner DE et al. Effect of Systemic Glucocorticoids in exacerbations of COPD. N Engl J Med 1999, 340: 1941-1947.
48.
Davies L et al. Oral corticosteroids in patients admitted to Hospital with exacerbation of COPD: a prospective randomized controlled trial. Lancet 1999, 354: 456- 460.
49.
Pauwels RA et al. Long-Term Treatment with Inhaled Budesonide in persons with mild COPD who continue smoking. NEJM 1999, 340: 1948-1953.
53.
Saetta M et al. CD8 T-Lymphocytes in Peripheral Airway of smokers with COPD. Am J Respir Crit Care Med 1998, 157: 822-836.
54.
Lams BEA et al. Immunopathology of the small airways submucosa in smokers with and without COPD. Am J Respir Crit Care Med 1998, 158: 1518-1523.
55.
Lipkin A et al. Otolaryngologists role in transtracheal oxygen therapy. Otolaryngol Head Neck Surg 1996, 115: 447-453.
56.
Levi-Valensi P et al. Sleep related oxygen desaturation and daytime pulmonary hemodynamics in COPD patients. Eur Respir J 1992, 5: 301-307.
57.
Keenan SP et al. Effect of noninvasive positive pressure ventilation on mortality in patients admitted with acute respiratory failure: a meta-analysis. Crit Care Med 1997, 25: 1685-1692.
58.
Bach JR et al. Consensus Conference: Noninvasive positive pressure ventilation. Respir Care 1997, 42: 361- 3.
59.
Poponick J M et al. Use of Ventilatory Support System (BiPAP) for Acute Respiratory Failure in the Emergency Department. Chest 1999, 116:166-171.
60.
Nava S et al. Noninvasive Mechanical Ventilation in Weaning of patients with Respiratory Failure due to COPD. Ann Intern Med 1998, 128:721-728.
61.
Girault C et al. Noninvasive Ventilation as a Systematic Extubation and Weaning Technique in Acute-onChronic Respiratory Failure. Am J. Respir. Crit.Care Med. 1999, 160: 86-92.
62.
Clinical Indications for Non Invasive Positive Pressure Ventilation in Chronic Respiratory Failure Due to Restrictive Lung Disease, COPD and Nocturnal Hypoventilation-A Concensus Conference Report. Chest 1999, 116: 521-534.
63.
Cray-Donald K et al. Nutritional Status and mortality in COPD. Am J Respir Crit Care Med 1996, 153: 961- 966.
64.
Schols AMWS et al. Weight loss is a reversible factor in the prognosis of COPD. Am J Respir Crit Care Med 1998, 157: 1791-1797.
65.
Burder L et al. Administration of growth hormone to underweight patients with COPD: a prospective, randomized, controlled study. Am J Respir Crit Care Med 1997, 156: 1800-1806.
66.
Ferreira IM et al. The influence of a 6 months of oral anabolic steroids on Body Mass and Respiratory Muscles in undernourished COPD patients. Chest 1998, 114: 19-28.
67.
Schols AMWJ et al. Plasma Leptin is Related to Proinflammatory Status and Dietary Intake in patients with COPD. Am J Respir Crit Care Med 1999, 160: 1220- 1226.
68.
Takabatake N et al. Circulating Leptin in Patients with COPD. Am J Respir Crit Care Med 1999, 159: 1215- 1219.
69.
Skeletal Muscle Dysfuction in COPD. A Statement of the American Thoracic Society and the European Respiratory Society. Am J Respir Crit Care Med. 1999, 159: S1-S40.
70.
Pulmonary Rehabilitation-1999. The Official Statement of ATS. Am J Respir Crit Care Med 1999, 159: 1666- 1682.
71.
Seersholm N, kok Jensen A. Clinical Features and prognosis of life time non-smokers with severe a1-antitrypsin deficiency. Thorax 1998, J3:265-268.
72.
Surviral and FEV1 decline in individuals with severe deficiency of a1 antitrypsin. The Alpha 1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med 1998, 158: 49-59.
73.
Dirksen A et al. A randomized clinical trial of a1-antitrypsin augmentation therapy. Am J Respir Crit Care Med 1999, 160: 1468-1472.
74.
Brantigan O et al. A surgical approach to pulmonary emphysema. Am Rev Respir Dis 1959, 39: 194-202.
75.
Cooper J D et al. Bilateral pneumonectony (volume reduction) for chronic obstructive pulmonary disease. J Thorac Cardiovasc Surg 1995, 109: 106-119.
76.
Cooper JD, Lefrak SS. Lung-reduction surgery: 5 years on. Lancet 1999, 353 (suppl): 26-27.
77.
Fessler HA, Wise RA. Lung Volume Reduction Surgery. Is Less Really More? Am J Respir Crit Care Med. 1999, 159: 1031-1035.
78.
Weg IL et al. Development of Pulmonary Hypertension after LVRS. Am J Respir Crit Care Med 1999, 159: 552-556.
79.
Sciurba F et al. Six-minute walk testing. Sem Respir Crit Care Med 1998, 19: 383-392.
80.
Ferguson G et al. Improved exercise performance following LVRS. Am J Respir Crit Care Med. 1998, 157: 1195-1203.
81.
Utz J et al. LVRS for emphysema. Out on a limbo without a NETT. Mayo Clin Proc. 1998, 73: 552-566.
82.
Anderson K et al. Comparison of two quality of life measures in patients undergoing lung volume reduction surgery. Am J Respir Crit Care Med 1998, 157(Suppl): A 749.
83.
Moy M et al. Quality of life domains of physical activity remain improved at greater than 9 months following LVRS. Am J Respir Crit Care Med 1998, 157 (Suppl): A 496.
85.
Gelb AF et al. Serial Lung Function and elastic recoil 2 years after LVRS. Chest 1998, 113:1497-150.
86.
Fessler HE, Permutt HS. Lung Volume Reduction Surgery and Airflow Limitation. Am J Respir Crit Care Med 1998, 157: 715-722.
87.
Sciurba EC et al. Improvenent in pulmonary function and elastic recoil after lung-reduction surgery for diffuse emphysena. N. Engl. J Med 1996, 334: 1095-1099.
88.
Lando Y et al. Effect of LVRS in diaphragm length in severe COPD. Am J Respir Crit Care Med 1999, 159: 796-805.
89.
Ingenito EP et al. Relation between preoperative inspiratory lung resistance and the outcome of LVRS for emphysema . N Engl J Med 1998, 338: 1181-1185.
90.
Maurer J et al. International Guidelines for the selection of lung transplant candidates. J Heart Lung Transplant 1998, 17: 703 709.
Share
RELATED ARTICLE
| eISSN: | 1791-4914 |
| ISSN: | 1105-848X |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
